Skip to main content
Fig. 1 | BMC Pharmacology and Toxicology

Fig. 1

From: Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis

Fig. 1

Effect of saroglitazar, fenofibrate, and pioglitazone on the body weight (A), liver weight (B), and percentage of the liver index (C) in the HF-induced NASH model. Values are expressed as mean ± SD (n = 7). NC = normal control, HF = high-fat emulsion, SARO = Saroglitazar, FENO=Fenofibrate, PIO=Pioglitazone. a and b indicate Significant difference against NC after 7 and 13 weeks, c indicates significant differences between NC, HF + SARO, and HF + FENO vs. HF, p < 0.001.*p < 0.05; **p < 0.01; and ns (nonsignificant) vs HF. # indicates significance vs. NC, p < 0.001

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us